Non-regulatory-arkiv | Affibody Medical AB

Affibody Medical Investor Relations

Categories:

Navigation:

Non-Regulatory

November 16, 2021

Affibody enters agreement with ACELYRIN for the development and commercialization of izokibep at a total deal value of USD 305 million plus royalties

Solna, Sweden, November 16, 2021. Affibody AB today announced a partnership agreement with ACELYRIN, INC., (“ACELYRIN”) to develop and commercialize izokibep, a bispecific molecule targeting interleukin-17A (IL-17), for multiple...

Non-Regulatory

September 9, 2021

Phase 2 LINNAEA Study Presented at EURETINA

Solna, Sweden, September 9, 2021. Affibody AB (“Affibody”) today announced that Professor Quan Dong Nguyen, Principal Coordinating Investigator of the LINNAEA Study, that will investigate izokibep (ABY-035) in uveitis,...

Non-Regulatory

August 27, 2021

Interim Report – January to June 2021

Affibody Medical AB (publ) (“Affibody” or “the Company”), a Swedish biotech company focused on developing next generation biopharmaceuticals based on its unique proprietary technology platforms: Affibody® molecules and Albumod®,...

Non-Regulatory

August 25, 2021

Affibody and Inmagene announce First Patient Dosed in the Global Phase 2 ASPIRE Trial of izokibep for patients with active Ankylosing Spondylitis

Affibody and Inmagene announce First Patient Dosed in the Global Phase 2 ASPIRE Trial of izokibep for patients with active Ankylosing Spondylitis. Partners will continue to file Investigational New...

Non-Regulatory

August 20, 2021

Affibody appoints Dr. Nikolai Brun as CMO

Solna, Sweden, August 23, 2021. Affibody AB (“Affibody”), a company developing innovative bi- and multi-specific next generation biopharmaceuticals, today announced it has appointed Dr. Nikolai Brun as CMO. Dr....

Non-Regulatory

June 2, 2021

Notice to attend Annual General Meeting

The shareholders of Affibody Medical AB (publ), corporate identity number 556714-5601 (the “Company” or “Affibody”) are hereby given notice to the Annual General Meeting to be held on Wednesday...

Non-Regulatory

May 14, 2021

Interim Report – January to March 2021

Affibody Medical AB (publ) (“Affibody” or “the Company”), a Swedish biotech company focused on developing next generation biopharmaceuticals based on its unique proprietary technology platforms: Affibody® molecules and Albumod™,...

Non-Regulatory

March 9, 2021

Affibody and Inmagene announce IND Clearance for izokibep (ABY-035) for the treatment of Non-infectious Non-anterior Uveitis

San Diego, U.S., Shanghai, China, and Solna, Sweden, March 9, 2021. Affibody AB (“Affibody”) and Inmagene Biopharmaceuticals (“Inmagene”) today announced that the U.S. FDA has cleared the novel interleukin-17...

Non-Regulatory

February 19, 2021

Year End Report 2020

Affibody Medical AB (publ) (“Affibody” or “the Company”), a Swedish biotech company focused on developing next generation biopharmaceuticals based on its unique proprietary technology platforms: Affibody® molecules and Albumod™,...